|
|
|
International events
|
Intercontinental Hotel, Paris
25 – 26 March, 2010
The INTS was invited to attend the 5th Finance & Investment in Qatar Forum enabling
Qatari companies and governmental institutions to meet French private entities and
public structures in multiple sectors.
Sheikh Hamad bin Jassim bin Jabor Al-Thani, Prime Minister and Minister of
Foreign Affairs, Qatar, and Mr. François Fillon, Prime Minister, France
Public Health was represented by prominent Qatari personalities such as HE Mr. Abdullah
bin Khalid Al-Qahtani, Minister of Public Health, Dr. Mohamed Fathy Saoud, President
to Qatar Foundation, and Dr. Youssef Al Horr, Chairman and Managing Director of
BQDRI (Barwa and Qatari Diar Research Institute).
On this occasion, Dr. Thierry Peyrard, Head of Unit at the CNRGS (French national reference
centre for blood groups) and Sophie Maréchal- Françon, Delegate for International
Activities, were lucky enough to have a 1to1 discussion with Dr. Hanan Mohammed
Al-Kuwari, MD, PhD, and Managing Director to HMC (Hamad Medical Corporation), Qatari
equivalent of our AP-HP. Most surprizingly hearing Dr. Al- Kuwari say “vous tombez
à pic !” , they were happy to discover she was also the proper contact for
transfusion medicine activities.
Managing 5 hospitals in Qatar, of which the unique blood transfusion operator, from
the blood donor to the recipient of blood components, and including IH, Dr. Al-Kuwari
expressed her wish to implement external audits of TM activities within a continuous
improvement quality scheme and for so doing, set up a close partnership with dedicated
specialists such as our institute.
For 4 years and the only example in the world except the USA, all public hospitals
in Qatar have indeed been awarded the JCI (Joint Commission International) accreditation,
acknowledging Qatar world-over healthcare system quality.
Hence Dr. Al-Kuwari’s interest when hearing that, highly involved in a quality system
management scheme and processes, most of our departments are either certified or
accredited from international quality standards as well, whatever ISO 17025 for
reference laboratories, or continuous education and training programs in transfusion
medicine areas such as blood donation, blood product preparation and quality control,
laboratory testing, blood banking, clinical transfusion, etc …
Besides, with our 2-year collaboration with the Armed Forces Transfusion Centre
in Riyadh (Saudi Arabia), another matching opportunity was found with the possibility
for HMC to send blood samples to our French reference centre for blood groups (CNRGS,
Paris) in view of solving complex IH cases.
Dr. Hanan Al-Kuwari, Managing Director, Hamad Medical Corporation,
Mr. Abdullah bin Khalid Al-Qahtani, Minister of Public Health, Qatar
With all such good mutual interest indicators, we are keen to develop a fruitful
cooperation in transfusion medicine areas with Qatar and to hopefully found some
partnership to serve our mutual scientific and financial interests.
|
|
MIC (Milano Convention Centre), Milan
9–12 June, 2010
Like every second year, Prof. Giuseppe Aprili, Chairman to the SIMTI (Società Italiana
di Medicina Trasfusionale e Immunoematologia), the Italian learned society in transfusion
medicine, kindly invited us to join the 39th Italian congress in Transfusion medicine,
hosting the EuroNet-TMS/EBA meeting held on 11 June 2010 in Milan.
Numerous speakers involved in the EuroNet-TMS and EBA networks have also taken part
in this congress as lecturers in various transfusion medicine fields:
Plenary sessions
Prof. Philippe Rouger: ‘Medical education in Transfusion
Medicine: the French experience in the European context’
Dr. Alex Aquilina: ‘A ‘European Corpus Docendi’ in Transfusion
Medicine’
Dr. Syria Laperche: ‘Transfusion safety in Europe and in developing
countries’
Dr. Cees van der Poel: ‘Management of risks of emerging infections’
Round Table with the European Transfusion Medicine Societies
Prof. Philippe Rouger, Prof. Alice Maniatis, Dr. Mario Muon, Dr. Marjeta Potocnik,
Dr. Brigitte Keller-Stanislawski, Dr Claudio Velati: ‘Blood
collection strategies and organization’
Parallel sessions
Dr. Claudio Velati: ‘RBC storage time and clinical effects’
and ‘The trend of occult HBV infection in blood donors in Italy’
Dr. Gilles Follea: ‘The French programme for self-sufficiency’
Dr. Jean-Pierre Cartron: ‘Recent advances in molecular immunohaematology’
Dr. Georges Andreu: ‘Is undertransfusion a real risk ?’
Castello Sforzesco, Milano
|
|
|
|
ICC (International Congress Centrum)
26 June – 1 July, 2010
3,395 participants
1,300 accepted abstracts
92 exhibiting companies
over 2,616 m2
1,610 booth personnel
5,163 attendees
altogether !
No less than 18 members from the EuroNet-TMS and EBA networks have delivered lectures
during the Berlin congress.
Also, our INTS scientific experts spoke on the following specificities:
Dr. G. Andreu: ‘EU-OBUP: Four aspects of surgical transfusion practice; evaluation
of methods’
Dr. C. Kaplan-Gouet: ‘Platelets: Fetal and neonatal alloimmunothrombo- cytopenia’
Dr. J-P. Cartron: ‘Blood group genetics and Physiology’
Dr. Y. Colin: ‘Functional reconstitution of a purified human RH/ammonia channel protein’
Dr. S. Laperche: ‘Sensitivity of 13 hepatitis B surface antigen assays for mutants
detection’
The ISBT Congress in Berlin also proved to be a most successful event for the INTS
thanks to its booth located right on the ‘bridge’, a very busy area of the ICC.
It has indeed allowed us to display all our activities, renewing already existing
contacts throughout France and Europe, and raising an interest in far-away visitors
from the Middle-East, Latin America, Africa, etc …
Due to this strong unexpected world-over visitors’ interest, specifically in our
services offer in education and training, continuous improvement and quality policy
implementation, blood group sample testing and audits, we are aware that it is time
for us to prepare and open to globalization.
Therefore, and to fulfil this enhancement requirement, we will strengthen the INTS
international presence by putting extra resources at the disposal of its international
development and increase its visibility on main international transfusion medicine
events.
|
|
‘The role of blood antigens and associated molecules in red cell biology: from molecular
approaches to clinical applications’
Auditorium, Institut National de la Transfusion Sanguine (INTS), Paris
15 – 17 September, 2010
History
Euro’SAT is another opportunity for all protagonists involved in the transfusion
development world to meet.
This 2-day international event under the INTS aegis has been taking place every
year since 1992 in the INTS Paris premises.
On this occasion, outstanding personalities in the blood transfusion sphere from
all over the world meet and exchange on experiences, practices, education programs,
figure out and promote scientific and technological advances in the transfusion
medicine field.
For 2 years, the Euro’SAT concept has focused on specific topics such as :
‘Adhesion molecules in red cell-endothelium interaction: impact
on sickle cell and malaria’, in 2008, followed by :
‘Molecular Biology of red cells : from research to diagnosis’ in
partnership with the SFTS (French Society of Blood Transfusion) in 2009.
In 2010, Euro’SAT commutes to a combined INTS – INSERM - Paris Diderot University
International Symposium dealing with ‘the role of blood group
antigens and associated molecules in red cell biology: from molecular approaches
to clinical applications’.
15 – 17 September 2010
INTS (Institut National
de la Transfusion Sanguine)
6, rue Alexandre Cabanel
75015 Paris - France
Click here to get information.
www.ints.fr/InternationalSymposium.aspx
Un symposium international sur les globules rouges
15 – 17 septembre 2010, INTS, Paris
Ce séminaire « Role of blood group antigens and associated molecules in red cell
biology : from molecular approaches to clinical applications » (rôle des
antigènes de groupes sanguins et des molécules associées dans la biologie du globule
rouge : de l’approche moléculaire aux applications cliniques) réunit les 180 spécialistes
mondiaux du sujet, dans un contexte où le globule rouge reste la cellule essentielle
de la transfusion sanguine.
En effet, malgré tous les travaux de recherche engagés au niveau international,
il n’existe pas de substitut artificiel pour ce type de cellule. La transfusion
sanguine continuera à reposer sur le prélèvement des donneurs pendant de très nombreuses
années, sachant que la complexité de fonctionnement des globules rouges est telle
que l’analyse d’un élément ne peut compenser les centaines d’éléments composant
cette cellule unique dans l’espèce humaine.
Ce globule rouge est un exemple qui associe la simplicité de sa fonction (le transport
de l’oxygène) et la complexité de son action (être capable de délivrer l’oxygène
et d’interagir avec les vaisseaux, les cellules et les organes).
Aussi, deux conséquences doivent être tirées, selon le discours introductif du Professeur
Philippe Rouger, Directeur Général de l’INTS :
- « D’une part, la nécessité de poursuivre une politique volontariste pour favoriser
le don de sang humain … c’est-à-dire la solidarité humaine.
- D’autre part, le développement des recherches concernant le globule rouge, tant
sur le plan fondamental qu’applicatif, pour répondre aux traitements de maladies
et au recours aux transfusions sanguines ».
Durant ces deux jours, les travaux ont montré, entre autres, que :
- La production « in vitro » de globules rouges humains n’en est qu’à une phase expérimentale
qui pourrait aboutir à des cellules matures pour certaines indications particulières
; le chemin est encore long et nécessite des études biologiques, immunologiques
et génétiques approfondies.
- Les modifications, in vitro, des globules rouges au laboratoire en sont au stade
expérimental, en particulier pour éviter les interactions néfastes avec les cellules
et les parois vasculaires, notamment dans le cadre de certaines maladies comme la
Drépanocytose.
- L’analyse de l’ADN à haut débit permet désormais de réaliser des groupes sanguins
et d’étudier les variants rares posant des problèmes transfusionnels délicats. Ainsi,
il devient possible de déterminer des groupes sanguins « sans utiliser de sang »,
mais des cellules telles que les cellules de la salive. Toutes ces évolutions technologiques
devraient conduire à une simplification des analyses médicales permettant de réaliser
en toute sécurité des transfusions sanguines compatibles.
- Le rôle des globules rouges comme source de récepteurs pour le développement de
maladies telles que le paludisme ; ainsi, cette cellule inachevée reste néanmoins
le transporteur nécessaire qui véhicule les virus ou parasites responsables de maladies.
C’est une pression sélective de la nature.
- La modélisation des structures du globule rouge, en particulier, des antigènes de
groupes sanguins. On passe ainsi des analyses biochimiques, immunologiques et génétiques
à une étape tridimensionnelle pseudo-virtuelle grâce aux progrès de l’informatique.
Les conséquences sont nombreuses, depuis l’étude des interactions cellulaires à
l’application chez les malades pour améliorer les compatibilités.
Symposium organisé par l’INTS, en association avec l’INSERM, les Universités Paris
VI et Paris VII, et l’Alliance Nationale pour les Sciences de la Vie et de la Santé.
Publications : AFP et APM International
Contact : Professeur Philippe Rouger – 06 09 57 76 02
International symposium on Red Blood Cells
15 – 17 September 2010 – INTS, Paris (France)
The symposium ‘Role of blood group antigens and associated molecules in red cell
biology : from molecular approaches to clinical applications’ gathered 180
world-over experts in this field, underlining that RBC (red blood cell) is still
here to stay as the core element in blood transfusion.
Even though multiple researches have been globally conducted on the subject, no
substitute to this particular blood cell has indeed ever been artificially found
as yet. Blood transfusion will not be overthrown for quite a long time, depending
on donors’ willingness, and with so intricate an RBC working that it makes the analysis
of an individual element unable to act as a substitute to hundreds of elements making
out this one and only specific human cell.
This RBC combines its simple function (oxygen transportation) with its complex action
(being able to deliver oxygen and interacting with vessels, cells and organs).
In this context, two consequences stem from the previous reflexions, as reported
by Prof. Philippe Rouger, Chief Executive Officer of the INTS in his foreword :
- « On the one hand, the necessity of pursuing a voluntarist strategy in favour of
blood donation, in other words, based on human solidarity.
- On the other hand, pursuing RBC research and development, both on fundamental and
practical levels, in order to fully address medical treatments and blood transfusions
».
Here is the outcome of works that have been carried out during this two-day symposium
:
- ‘in vitro’ production of human RBCs is only at an experimental stage, likely to
produce mature cells able to treat particular indications ; but there is still a
long way to go that will require in-depth biological, immunological and genetic
tests.
- Also in an experimental stage, ‘in vitro’ RBC modifications in the laboratory, specifically
meant to escape from harmful interactions with cells and vascular walls, for instance
in the sickle cell disease.
- Nowadays, the high speed DNA analysis allows for carrying out new blood groups and
studying rare variants inducing tough transfusion issues. Therefore it turns out
to be possible to determine blood groups ‘with no blood’ but only from cells such
as those in saliva. All such cutting edge technological upgrades are expected to
give way to a simplification of medical analyses allowing for fully safe compatible
blood transfusions.
- The role of RBC as a sensor for the development of diseases such as malaria ; nevertheless,
this unfinished cell still is the carrier for viruses or parasites to cause diseases.
This is what we can call a selective natural pressure phenomenon.
- The RBC structure modelling, in particular, of blood group antigens. IT upgrading
developments allow to start from biochemical, immunological and genetic analyses
to reach a pseudo-virtual tridimensional stage. Numerous consequences stem from
that, such as the study of cell interactions or the application in patients for
improving compatibilities.
Symposium set up by the INTS, in association with INSERM, Paris VI and Paris VII
Universities, and AVESAN (National Alliance for Life and Health Sciences).
Publications : AFP and APM International
Contact : Prof. Philippe Rouger – 00 33 (0)6 09 57 76 02
|
|
Amphithéâtre Jean Dausset, Institut National de la Transfusion Sanguine, Paris (France)
7 October, 2010
|
under the aegis of the French Society of Blood Transfusion (SFTS)
Subject : « Réduction de pathogènes des concentrés de plaquettes et gestion des
risques » (Pathogen reduction in platelet concentrates and risk management)
With the kind participation of :
Gilles Delage, HémaQuébec – Canada
William Murphy, Blood Transfusion Service, Dublin, Ireland
Jean-Daniel Tissot, Blood Transfusion Service, CHU Lausanne, Switzerland
From 11:40 am to 01:20 pm, experiences and status in Canada, Ireland and Switzerland
will be displayed and long-term consequences in transfusion practices will be specifically
discussed.
A reconciliation of experiences and practices around the main subject will be carried
out by René Amalberty, expert from the High Health Authority (HAS, Paris).
|
|
Baltimore Convention Centre, Maryland, USA
9 – 12 October, 2010
‘Mark your calendar now and plan to join us in Baltimore, Maryland for the AABB Annual
Meeting & CTTXPO 2010 and learn the latest in blood banking, transfusion medicine
and cellular and related biological therapies, advance your career, explore state-of-the-art
products and services and network with colleagues.’
Like every year in October, the AABB is setting up its annual meeting.
This year, Cellular Therapy is emphasized, but other blood transfusion applications
such as blood groups, rare bloods, platelet immunology, ... will also be talked
about.
Dr. Cécile Kaplan-Gouet, Head of the INTS Platelet Immunology Dept., will take part
in the event as a member of the scientific and administrative committee.
Will also be contributing, Dr. Thierry Peyrard, Head of Unit at the CNRGS, with
2 presentations:
- ‘The Vel- rare blood phenotype in France: a 15-year experience’, an
abstract published in vol. 50, Transfusion (Supplément, 2010)
- ‘The Anti-e and Antibody to a High- prevalence Rh Antigen Made by RHCE*ceMO/RHCE*cE
and RHCE*ceMO/RHCE*ceMO People are not Anti-hr s /Anti-hr B nor Anti- Hr/Anti-Hr
B Respectively’, an abstract published in vol. 50, Transfusion (Supplément,
2010) displayed as a poster at AABB.
|
|
Palais des Congrès, Beaune, Côte d’Or (France)
21 – 24 October, 2010
under the aegis of ISBT & with the support of :
Dr. Cécile Kaplan-Gouet, Head of the Platelet Immunology Dept at the INTS (French
Institute of Blood Transfusion), will chair the XIth
European Symposium on Platelet and Granulocyte Immunobiology to be held in Beaune
(Côte d’Or, France) from 21 to 24 October 2010.
Experts in this specific field and from all over the world (Australia, Canada, Europe,
Israel, Japan, the USA, ...) will meet in the cheerful capital of Burgundy wines
and deliver state-of-the-art lectures on topics ranging from fundamental science
to clinical applications.
Besides, we shall be glad to fulfil the wish of some experts from Finland, Slovenia,
China and Israel of visiting the Platelet Immunology laboratory at the INTS during
their 25 to 29 October stay in France.
During the seminar, and to encourage the younger generation, time will be allowed
for some of them to display short presentations selected from abstracts.
www.sfts.asso.fr/sympo-platelet
to know more and/or register
click
here to read the program:
This event will also set forth an unparalleled occasion for transfusion medicine
professionals to meet our Education & Training team on the spot. Whatever country
and language, and on simple request, they will be proposed a short preview of 48
training modules, delivered in French/ English, in close consistency with expectations.
Specifically, we will take the opportunity of this high-flying symposium to announce
a new English-spoken session about advances in platelet and immuno-haematology,
stem cells, virology, blood groups to be scheduled in 2011 (date to be settled in
the following weeks).
If interested in this brand-new training session, or in any other education program
we propose, please drop in our INTS booth in Beaune and we will have the pleasure
to inform you accordingly !
We look forward to welcome you there !
insc-sympo-platelet@europa-organisation.com
Ph. +33 (0)5 34 45 26 45
|
|
Hyderabad, Brahma Kumaris Shanti Sarovar, India
12 – 14 November 2010
CMEs, Wet Workshops, Plenary & Keynote Lectures, Oral & Poster presentations
"ISBTI is the only organization in the country (ndlr:India) working for promotion
of Voluntary Blood Donation and supply safe blood in the country. (...). The Society
has done admirable job by banning the professional blood donor through judgment
of Honorable Supreme Court in 1996, established National and State Blood Transfusion
Council and assisted the Govt. of India for Implementing National Blood Policy.
This is a national organization for Blood Banking, Transfusion Medicine and Donor
Recruitment activities in India. Established on 28th December 1973 in Chandigarh,
the society has risen to a national level with about 2000 members on its
rolls. The society is registered under the Society Registration Act as a Voluntary
Organization".
800 delegates from all over India and international transfusion medicine professionals
from Asian and Middle-Eastern countries are expected to attend this event.
On this occasion, Dr. Cécile Kaplan-Gouet, Head of the INTS Platelet Immunology
Dept., was invited by the ISBTI to deliver a lecture on 'Fetal and Neonatal alloimmune
thrombocytopenia - Diagnosis and therapy' on 12 November.
Industrial companies from Europe, the USA, etc ... will be exhibiting at this international
event. So will the INTS, with their 9 sqm stall held for the whole congress duration
by Education & Training and international activity representatives, in favour of
an increased visibility and promotion of our activities.
Obvious occasions will be granted to brief world-over visitors on the INTS new higher
education curricula as well as CME, CPD, and e-learning sessions. Also, 1to1 meetings
will take place on the spot, previously scheduled with 'hot prospects' interested
in education, (rare) blood groups, quality control, ... only to mention a few.
Reach here for the
Registration contact:
|
Cairo, Egypt
December 1 – 4, 2010
|
The Royal Tropical Institute (KIT), Amsterdam, The Netherlands
9 – 11 February 2011
Next EuroNet-TMS and EBA meeting is to take place in Amsterdam on Friday, 11 Feb,
2011 (pm).
The date was also chosen with the possibility for all members to combine with attending
the 13th International Haemovigilance Seminar, due to take place in Amsterdam from
9 Feb. pm to 11 Feb. am, under the aegis of:
- ISBT (International Society of Blood Transfusion)
- IHN (International Haemovigilance Network)
- TRIP (Transfusion Reactions in Patients).
www.eurocongres.com/ihs
(article and pic, courtesy of rangaku1976/Flickr)
The INTS exhibitor at the
13th International
Haemovigilance Seminar
from 9 February pm to 11 February 2011
We will be happy to welcome you on the INTS booth at the Royal Tropical Institute
(KIT), Mauritskade 63, 1092 AD in Amsterdam !
Please send your information request to:
smarechal@ints.fr
and/or click here to register
Royal Tropical Institute (KIT)
The Royal Tropical Institute (KIT) was founded in 1910 as the ‘Colonial Institute’
to study the tropics and to promote trade and industry in the (at that time) colonial
territories of the Netherlands. It was founded on the initiative of a number of
large companies, with government support, making it an early example of a public-private
partnership.
Since 1926, KIT has been housed in a historic building in Amsterdam especially designed
by the architect J.J. van Nieukerken and his sons. The building is richly adorned
with decorative features and symbols referring to the different cultures of the
world and the colonial history of the Netherlands.
Today the 'KIT' is an independent centre of knowledge and expertise in the areas
of international and intercultural cooperation, operating at the interface between
theory and practice and between policy and implementation. The Institute contributes
to sustainable development, poverty alleviation and cultural preservation and exchange.
|
|
|